Last reviewed · How we verify

Lacidipine & Amlodipine — Competitive Intelligence Brief

Lacidipine & Amlodipine (Lacidipine & Amlodipine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dihydropyridine calcium channel blocker. Area: Cardiovascular.

marketed Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Lacidipine & Amlodipine (Lacidipine & Amlodipine) — Korea University Guro Hospital. Lacidipine and amlodipine are dihydropyridine calcium channel blockers that inhibit L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reducing blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lacidipine & Amlodipine TARGET Lacidipine & Amlodipine Korea University Guro Hospital marketed Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel
Candesartan cilexetil/Amlodipine besylate Candesartan cilexetil/Amlodipine besylate HK inno.N Corporation marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel
Amlodipine placebos Amlodipine placebos Shenzhen Ausa Pharmed Co.,Ltd marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
amlodipine/hydrochlorothiazide amlodipine/hydrochlorothiazide Shanghai Jiao Tong University School of Medicine marketed Calcium channel blocker / Thiazide diuretic combination L-type voltage-gated calcium channel (amlodipine); Sodium-chloride cotransporter (hydrochlorothiazide)
Amlodipine (Norvasc) Amlodipine (Norvasc) Bayer marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Amlodipine+intensive antihypertensive therapy Amlodipine+intensive antihypertensive therapy Beijing Tiantan Hospital marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Losartan and Amlodipine Losartan and Amlodipine Centro Universitario de Ciencias de la Salud, Mexico marketed Angiotensin II receptor antagonist + Calcium channel blocker combination AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dihydropyridine calcium channel blocker class)

  1. Bayer · 1 drug in this class
  2. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 drug in this class
  3. Haseki Training and Research Hospital · 1 drug in this class
  4. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
  5. Korea University Guro Hospital · 1 drug in this class
  6. Nanjing Yoko Biomedical Co., Ltd. · 1 drug in this class
  7. Organon and Co · 1 drug in this class
  8. Pfizer Inc. · 1 drug in this class
  9. University Hospital Hradec Kralove · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lacidipine & Amlodipine — Competitive Intelligence Brief. https://druglandscape.com/ci/lacidipine-amlodipine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: